VEGFR-2 Expression in Glioblastoma Multiforme Depends on Inflammatory Tumor Microenvironment

International Journal of Inflammation
Jana JaalToomas Asser

Abstract

Glioblastoma multiforme (GBM) is one of the most angiogenic tumors. However, antiangiogenic therapy has not shown significant clinical efficacy. The aim of our study was to evaluate the impact of inflammatory tumor microenvironment on the expression of vascular endothelial growth factor receptor 2 (VEGFR-2). Surgically excised primary GBM tissues were histologically examined for overall extent of inflammation (score 1-3). After immunohistochemistry, the tissue expression of ICAM-1 (optical density), the number of VEGFR-2 positive (VEGFR-2+) blood vessels (per microscopic field), and the endothelial staining intensity of VEGFR-2 (score 0-3) were determined. In GBM, the extent of inflammation was 1.9 ± 0.7 (group mean ± SD). Mean optical density of inflammatory mediator ICAM-1 was 57.0 ± 27.1 (pixel values). The number of VEGFR-2+ blood vessels and endothelial VEGFR-2 staining intensity were 6.2 ± 2.4 and 1.2 ± 0.8, respectively. A positive association was found between endothelial VEGFR-2 staining intensity and the extent of inflammation (p = 0.005). Moreover, VEGFR-2 staining intensity correlated with the expression level of ICAM-1 (p = 0.026). The expression of VEGFR-2, one of the main targets of antiangiogenic therapy, depend...Continue Reading

References

Sep 1, 1999·International Journal of Experimental Pathology·K NarkoA Ristimäki
Dec 30, 1999·Journal of Leukocyte Biology·K A Roebuck, A Finnegan
Aug 5, 2000·Free Radical Biology & Medicine·A K Hubbard, R Rothlein
Oct 17, 2002·Endothelium : Journal of Endothelial Cell Research·Gerben A KoningGert Storm
Feb 22, 2005·Current Drug Targets. Inflammation and Allergy·Antonella Naldini, Fabio Carraro
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 14, 2005·Neurological Research·Hongguang HuangRolf Mentlein
Mar 7, 2006·Biochemical and Biophysical Research Communications·Jianhua S YaoGuo-Yuan Yang
Feb 23, 2008·Angiogenesis·Janice A NagyHarold F Dvorak
Feb 10, 2009·Current Pharmaceutical Design·Zhao Ming David DongRoberto F Nicosia
Feb 24, 2009·Current Opinion in Cell Biology·Marja LohelaKari Alitalo
Oct 15, 2009·Nature Reviews. Neurology·Andrew D NordenPatrick Y Wen
Apr 24, 2010·Journal of Oncology·Ruman RahmanRichard Grundy
Jun 16, 2010·Angiogenesis·Nirupama DeshpandeJürgen K Willmann
Jun 19, 2010·Angiogenesis·Willem J M Mulder, Arjan W Griffioen
Sep 22, 2010·Journal of Korean Neurosurgical Society·Chang-Hyun LeeSeung Hoon Lee
Oct 12, 2011·Oncology·Elizabeth A KuczynskiBrenda L Coomber
Jan 10, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Emanuele CrocettiUNKNOWN RARECARE working group
Feb 2, 2012·Chemotherapy Research and Practice·Eleni Timotheadou
Mar 15, 2012·Expert Opinion on Investigational Drugs·Katharina Seystahl, Michael Weller
Jul 27, 2012·Journal of Neuro-oncology·Edward PanMarc Chamberlain
Aug 4, 2012·The American Journal of Pathology·Matthew E Hardee, David Zagzag
Oct 27, 2012·Neuro-oncology·Teri N KreislHoward A Fine
Aug 14, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy T BatchelorMartin van den Bent
Oct 25, 2013·Expert Review of Anticancer Therapy·Patrick RothMichael Weller
Feb 21, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
Feb 21, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Mar 26, 2014·Journal of Neurosurgical Anesthesiology·Maurice S Albin

❮ Previous
Next ❯

Citations

Oct 20, 2018·Scientific Reports·Metin AkayJay-Jiguang Zhu
May 10, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Magali ToussaintPeter Brust

❮ Previous
Next ❯

Software Mentioned

SPSS
ImageJ

Related Concepts

Related Feeds

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.